

**STIC-FPAS**

**From:** Davis, Minh-Tam  
**Sent:** Tuesday, February 17, 2004 1:09 PM  
**To:** STIC-FPAS  
**Subject:** PCT/CN 98/00199 09/22/1998

I am working with a 371 for this PCT. It lacks however an abstract. Can you send me an abstract from this PCT?

Thankyou.

MINH TAM DAVIS

ART UNIT 1642

RESEM

ROOM 3A24, MB 3C18

272-0830

## Hit List

Number of  
documents to display is limited to 10 for FULL format

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results – Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: WO 200017349 A1, CN 1279716 A

L1: Entry 1 of 1

File: DWPI

Mar 30, 2000

DERWENT-ACC-NO: 2000-283577

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New NPCABC08 polypeptide comprising a 468 amino acid sequence, useful in the treatment of cancer, leukemia, diabetes mellitus, kidney disease and autoimmune disease

INVENTOR: CHEN, J; FU, G ; SONG, H

## PATENT-ASSIGNEE:

ASSIGNEE

CODE

UNIV SHANGHAI MEDICAL

UYSHN

UNIV SHANGHAI SECOND MEDICAL

UYSHN

PRIORITY-DATA: 1998WO-CN00199 (September 22, 1998)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 200017349 A1</u>	March 30, 2000	E	031	C12N015/12
<u>CN 1279716 A</u>	January 10, 2001		000	C12N015/12

DESIGNATED-STATES: CN US

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 200017349A1	September 22, 1998	<u>1998WO-CN00199</u>	
CN 1279716A	September 22, 1998	1998CN-0811405	
CN 1279716A	September 22, 1998	<u>1998WO-CN00199</u>	

INT-CL (IPC): C12 N 15/12

ABSTRACTED-PUB-NO: WO 200017349A

BASIC-ABSTRACT:

NOVELTY - A NPCABC08 polypeptide, member of the secretogranin III (SgIII) family of polypeptide, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated polypeptide (P1) selected from:

(a) an isolated polypeptide (Pla) comprising an amino acid sequence having at least 70%, 80%, 90% or 95% identity to the 468 amino acid sequence (I) given in the specification, over its entire length;

(b) an isolated polypeptide comprising the sequence of (I);

(c) an isolate polypeptide which is (I);

(2) an isolated polynucleotide (N1) selected from:

(a) an isolated polynucleotide comprising a nucleotide sequence encoding Pla;

(b) an isolated polynucleotide comprising a nucleotide sequence which has at least 70%, 80%, 90% or 95% identity over its entire length to a nucleotide sequence encoding (I);

(c) an isolated polynucleotide comprising a nucleotide sequence which has at least 70%, 80%, 90% or 95% identity to the 2017 nucleotide sequence (II) given in the specification, over its entire length;

(d) an isolated polynucleotide comprising a nucleotide sequence encoding (I);

(e) an isolated polynucleotide which is (II);

(f) an isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of (II) or its fragment; or

(g) a nucleotide sequence complementary to the polynucleotides of (a) to (f);

(3) an antibody immunospecific for P1;

(4) a method of treatment of a subject:

(a) in need of enhanced activity or expression of P1 comprises:

(i) administering to the subject an effective amount of an agonist to P1; and/or

(ii) providing to the subject an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide in a form so as to effect production of the polypeptide activity in vivo; or

(b) having need to inhibit activity or expression of P1 comprising:

(i) administering to the subject an effective amount of an antagonist to the P1; and/or

(ii) administering to the subject a nucleic acid molecule that inhibits the expression of a nucleotide sequence encoding P1; and/or

(iii) administering to the subject an effective amount of a polypeptide that competed with P1 for its ligand, substrate or receptor;

(5) a process for diagnosing a disease or a susceptibility in a subject related to expression or activity of P1 in a subject comprising:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding P1 in the genome of the subject; and/or

(b) analyzing for the presence or amount of polypeptide expression in a sample derived from the subject;

(6) a method for screening to identify compounds which stimulate or which inhibit the function of P1 comprises a method selected from:

(a) measuring the binding of a candidate compound to P1 (or to the cells or membranes bearing P1) or its fusion protein by means of a label directly or indirectly associated with the candidate compound;

(b) measuring the binding of a candidate compound to P1 (or to the cells or membranes expressing the polypeptide) or its fusion protein in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of P1, using detection systems appropriate to the cells or cell membranes expressing P1;

(d) mixing a candidate compound with a solution containing P1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding P1 in cells by using for example an ELISA (enzyme-linked immunosorbant assay) assay;

(7) an agonist or antagonist of P1;

(8) an expression system comprising a polynucleotide capable of producing P1, where the expression system is present in a compatible host cell;

(9) a process for producing a recombinant host cell comprising transforming or transfecting a cell with the expression system of (8) such that the host cell, under appropriate culture conditions, produces a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of (I) over its entire length;

(10) a recombinant host cell produced by the process of (9);

(11) a membrane of a recombinant host cell of (10) expressing a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of (I) over its entire length; and

(12) a process for producing a polypeptide comprising culturing a host cell of (10) under conditions sufficient for the production of the polypeptide and recovering the polypeptide from culture.

ACTIVITY - Cytostatic; antidiabetic; immunosuppressive.

MECHANISM OF ACTION - None given.

USE - NPCABC08 polynucleotides and polypeptides are useful in the treatment of cancer, leukemia, diabetes mellitus, kidney disease and autoimmune disease. They are also useful in detecting diseases associated with inappropriate NPCABC08 activity or levels.

CHOSEN-DRAWING: Dwg.0/0.

TITLE-TERMS: NEW POLYPEPTIDE COMPRISE AMINO ACID SEQUENCE USEFUL TREAT CANCER  
DIABETES MELLITUS KIDNEY DISEASE DISEASE

DERWENT-CLASS: B04 D16

CPI-CODES: B04-C01G; B04-E03F; B04-E08; B04-F0100E; B04-G01; B04-N02A0E; B11-C08E;  
B12-K04A; B12-K04E; B12-K04F; B14-G02D; B14-H01; B14-L01; B14-L06; B14-N10; B14-S04;  
D05-H08; D05-H09; D05-H11; D05-H12A; D05-H12E; D05-H14; D05-H17A6;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

M423 M710 M750 M905 N102 N135 N161 P433 P632 P633

P723 P816 Q233

Specific Compounds

A00NST A00NSA A00NSN

Chemical Indexing M1 \*02\*

Fragmentation Code

M423 M710 M750 M905 N102 N135 N161 P433 P632 P633

P723 P816 Q233

Specific Compounds

A012PT A012RA A012PN

Chemical Indexing M1 \*03\*

Fragmentation Code

M423 M710 M720 M750 M781 M905 N102 N135 P433 P632

P633 P723 P816 P831 Q233 Q505

Specific Compounds

A00H1T A00H1A A00H1D A00H1N A00H1P

Chemical Indexing M1 \*04\*

Fragmentation Code

M423 M710 M720 M750 M781 M905 N102 N135 P433 P632

P633 P723 P816 P831 Q233 Q505

Specific Compounds

A00H3T A00H3A A00H3D A00H3N A00H3P

Chemical Indexing M1 \*05\*

Fragmentation Code

M423 M710 M750 M905 N102 N135 Q233

Specific Compounds

A00GTA A00GTN

Chemical Indexing M1 \*06\*

Fragmentation Code

M423 M710 M905 Q233

Specific Compounds

A00C8N

Chemical Indexing M6 \*07\*

Fragmentation Code

M905 P433 P632 P633 P723 P816 P831 Q233 Q505 R515

R521 R624 R627 R633 R637 R639

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2000-085689

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawn De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

Terms	Documents
1998wo-cn00199.ap,prai.	1

Display Format: [Previous Page](#)[Next Page](#)[Go to Doc#](#)